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Introduction: Ovarian metastases occur in 3 to 8% of women with primary colon cancer. In the setting of a
pre-existing colorectal carcinoma this would constitute a hereditary non-polyposis colorectal cancer, Lynch 2
syndrome, accounting for 5 to 10% of colon cancer cases. We unveil a case of ‘giant’ ovarian tumors mimicking
primary ovarian cancer; ostensibly the first reported in East Africa.
Case presentation: A 58-year-old African woman was diagnosed with colorectal adenocarcinoma in June 2009.
She had a right hemicolectomy with the tumor staged as regional cancer, following histopathological examination.
Chemotherapy was administered both adjuvantly and 1 year later for what was thought to be a recurrence of
tumor. Despite this, her general condition deteriorated. Following re-evaluation and an exploratory laparotomy she
was found to have bilateral ‘giant’ ovarian tumors, with peritoneal seedlings and subcutaneous metastases (colonic
in origin). A bilateral salpingo-oophorectomy was done, accompanied by histopathological analysis with institution
of chemotherapy for ovarian cancer. Following immunohistochemistry tests and microsatellite instability analysis it
was found that the ovarian tumors were secondaries from the colon. She was also identified as a Lynch syndrome
case or a case of sporadic microsatellite instability, although with no suggestive family cancer history. The treatment
regimen was changed to suit metastatic disease.
Conclusions: The case presents a diagnostic and thus treatment conundrum. Two primary tumors (suspected
Lynch syndrome) had been perceived yet there is actually only metastatic colorectal cancer. We also have a rare
and unusual metastatic presentation: ‘giant’ bilateral ovarian tumors and subcutaneous nodules, concurrently.
Further still, she is a case of probable Lynch syndrome, requiring genetic analysis for definitive classification and
surveillance for hereditary non-polyposis colorectal cancer-associated cancers.
Important inferences are drawn. Firstly, ‘giant’ ovarian tumors diagnosed as primary ovarian cancer may actually be
colonic secondaries. Secondly, immunohistochemistry and microsatellite instability analysis tests ought to be part of
the diagnostic package in colon cancer management, particularly for identifying tumor origin and the Lynch
syndrome (a condition which has had little attention in resource-limited countries). Thirdly, multidisciplinary team
collaboration is emphasized in colorectal cancer management.
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Colorectal cancer is among the top five leading forms of
cancer among women in Uganda [1]. In some resource-
rich countries it is the second leading cause of cancer-
related deaths [2]. The majority of colorectal cancer
cases are sporadic, occurring in individuals without any
known familial predisposition. Approximately 20% of all
cases occur with a related family history, but most of the
predisposing genetic factors are not yet identified.
The ovaries are an uncommon secondary site for
metastatic colorectal carcinoma; the liver and lungs be-
ing commoner. In general, the ovaries are the organ of
the female reproductive system most commonly affected
by metastases [3]. Ovarian metastases occur in 3 to 8%
of women with primary colon cancer [4], with their
prevalence at the time of diagnosis being 1.1%. Following
surgery, the metachronous prevalence remains 1.1% [5].
Colorectal cancer accounts for 65% of the malignancies
found to have ovarian metastases at the time of primary
surgery. Metastatic gastrointestinal cancers frequently
mimic an ovarian primary in both pre- and postmeno-
pausal women [6], yet covert gastrointestinal tumors may
present as advanced ovarian cancer. Subcutaneous or skin
metastases account for only 5% of metastases [7,8].
The occurrence of a primary ovarian carcinoma,
metachronously, with colorectal carcinoma is a well-
known entity. It is a presentation of hereditary non-
polyposis colorectal cancer (HNPCC; Lynch syndrome),
the commonest hereditary type of colon cancer [2], and
constitutes 5 to 10% of colorectal cancer cases [9]. There
are two phenotypic types of Lynch syndrome: type 1 and
2. Lynch syndrome 1 presents with two separate colorectal
cancers, whereas Lynch syndrome 2 manifests as colorec-
tal cancer with another extra-colonic cancer. The extra-
colonic cancers are: endometrial, gastric, urinary tract,
biliary tract, pancreatic, small bowel, brain and skin.
Rarely, ovarian cancer may manifest in Peutz–Jeghers
syndrome. Ovarian cancer is the second most common
extra-colonic site in women, its overall lifetime risk of
development being 6.7% [10].
Lynch syndrome is inherited in an autosomal domin-
ant pattern. Because of the absence of an overt polyposis
phenotype, it can be the most challenging hereditary
colorectal syndrome to recognize. Germline mutations
in one of several deoxyribonucleic acid (DNA) mismatch
repair (MMR) genes are responsible for this syndrome.
The MMR genes in the presence of microsatellites,
define the Lynch syndrome genotype. Recent studies
have suggested a median age of diagnosis of associated
colorectal cancers of 61.2 years and a lifetime colorectal
cancer risk of 52.2% in women [10]. Synchronous and
metachronous tumors are frequently observed.
To establish a diagnosis of Lynch syndrome, every
patient with colorectal cancer should undergo a detailedfamily history. A suggestive family history is delineated
by the Amsterdam II criteria, and Bethesda guidelines to
maximize sensitivity [2]. Specific features that should raise
suspicion are: multiple family members affected with colo-
rectal cancer or associated extra-colonic tumors; young
age at diagnosis of colon cancer; or multiple Lynch
syndrome-associated cancers in a single individual. Cur-
rently, fulfillment of the Amsterdam II criteria is insuf-
ficient to establish a definitive diagnosis of Lynch
syndrome, and molecular testing is required for this pur-
pose. We are very limited in capacity to conduct these
tests in Uganda.
Case presentation
Our patient is a 58-year-old African-Ugandan woman of
Bantu ethnicity. She was diagnosed with adenocarcinoma
of the colon in June 2009, following her presentation to
hospital with features of acute intestinal obstruction. At
the time, she had complaints of on-and-off partial consti-
pation for 2 weeks, abdominal pain and distension for 2
days, and vomiting for 1 day. She was dehydrated and
wasted. Following resuscitation, an exploratory lapa-
rotomy was done at which she was found to have a
circumferential tumor of the ascending colon causing ob-
struction. There was grossly distended bowel proximal to
it and mesenteric lymphadenopathy. There was no ascites,
and all other abdominopelvic organs were normal. A
cecostomy with excisional biopsy of a mesenteric lymph
node was done. Histopathologic examination showed an
adenocarcinoma within the lymph node.
She had previously been unwell for about 3 years prior
to this condition, with on-and-off periods of constipation
and loose stool motions, alternately. These episodes
lasted for between 1 week and 1 month, with relative pe-
riods of wellbeing lasting up to a month. Concurrently,
she had periods of abdominal pain. This was diffuse,
although largely right-sided, was of insidious onset and
dull in nature. There was some pain relief with oral anal-
gesics. Constipation was relieved with a warm soap
enema on one occasion. She had never felt any mass per
abdomen. There was neither a history of melena stools
nor blood in her stool. Despite her good appetite, she
had lost weight over a period of about 4 months.
Six weeks after her emergency operation she under-
went a definitive standard open right hemicolectomy.
She had no ascites, peritoneal seeding or para-aortic
lymphadenopathy. Her liver, ovaries, uterus and pouch
of Douglas were normal. Histopathologic examination
staged the tumor as pT2, N2, M0: Dukes C. She had a
relatively quiescent clinical period after approximately 2
months of recovery from the direct effects of surgery.
Adjuvant chemotherapy was instituted. She had the
Mayo regimen (5-fluorouracil (5-FU) and leucovorin)
instituted 3 months after her first presentation, for a
Figure 1 Photograph after bilateral oophorectomy. Area marked
A shows an abdominal wall hernia at site of previous abdominal
stoma. It is filled with ascitic fluid. Deep blue arrows point to
subcutaneous metastases, whereas red arrow points to umbilical
metastasis (Sister Mary Joseph’s nodule).
Figure 2 Photograph of ‘giant’ ovaries following
oophorectomy. Note the relative size of the ovaries compared with
neighboring surgical instruments: artery forceps and
diathermy pencil.
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FOLFOX regimen (5-FU, oxaliplatin and leucovorin)
were administered, after the Mayo regimen, for another
6 months. Following this she remained weak and quite
limited in carrying out her routine activities. She is a
widow with eight children, all alive and well. There is no
family history suggestive of colorectal, breast, ovarian,
uterine, renal, stomach or skin cancer.
At the end of 2010 she developed gradual abdominal
distension, with the feeling of a mass in the hypogastric
and left iliac region. This prompted her to return to the
oncology unit 4 months later. She described her condi-
tion as having generally deteriorated. She felt weaker,
spent more time in bed, and reported progressive an-
orexia and weight loss. Bowel habits were essentially
normal. On examination, she was sick looking, wasted
and had bilateral pedal edema. There was no significant
lymphadenopathy, jaundice or digital clubbing. Abdom-
inal examination revealed asymmetrical distension,
normal movement with respiration and the presence of
a midline incision scar. She had a right iliolumbar inci-
sional hernia and moderate ascites. There was a mass in
the left lower abdominal quadrant, measuring about 15
by 15cm in dimension. It was smooth, regular, firm,
mobile and felt to arise from the pelvis to just above the
umbilicus. Other systemic examination was unremarkable.
A diagnosis of recurrent colorectal carcinoma was made.
An abdominal ultrasound scan and the routine hepatic,
renal and hematological tests were done. On ultrasound
scan her liver was found to be normal although she had
ascites and a right pleural effusion. The other laboratory
tests were normal. She was started on capecitabine (oral
5-FU) and leucovorin for 6 months, followed by the
FOLFOX regimen again. Throughout this period there
was no remarkable improvement. Abdominal distension
progressively increased and she had to have regular
peritoneocentesis for ascitic relief.
In May 2012 her condition was re-evaluated. She was
frail and had grade 2 edema. There was a Sister Mary
Joseph’s nodule and scattered periumbilical, hypogastric
and epigastric subcutaneous nodules (Figure 1). She had
a prominent right-sided incisional hernia in the
iliolumbar region. This was the area she had had a
cecostomy placed. She had gross ascites and a large mass
per abdomen, extending from the pelvis to just about
5cm inferior to the xiphisternum in the epigastrium;
most of the abdomen was occupied by it. It was irregu-
lar, firm and mobile in the transverse plane. A computer-
ized tomography scan was done and it indicated that the
mass (dimensions: 168 × 279 × 273mm) was arising
from the pelvis; uterine, ovarian or rectal in origin.
Three months later, an exploratory laparotomy was done
which revealed bilateral ‘giant’ ovarian tumors (Figure 2).
They were freely mobile with normal fallopian tubes,and no attachment to other intra-abdominal or pelvic
organs. The uterus was atrophic and free of any tumor
infiltration. The liver was regular in texture and
consistency, and no masses were palpated. Extensive
peritoneal seedlings were present. Bilateral salpingo-
oophorectomy was done along with drainage of 3L of
hemorrhagic ascitic fluid. The left ovary was larger than the
right one with widest diameters being 30cm and 28cm,
respectively (Figure 2). Histopathologic findings were
interpreted as well-differentiated cystadenocarcinoma
of the ovaries (serous type) (Figure 3).
It was thought at the time that this could be a case of
either Lynch 2 syndrome (colorectal and ovarian cancer)
or metastatic colon cancer. She was then started on a
Figure 3 Hematoxylin and eosin-stained sections of the ovary. Photomicrograph A (under ×4 magnification objective) shows malignant
glands in the ovarian stroma. Photomicrograph B shows the malignant glands under higher magnification (×10 magnification).
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of ovarian carcinoma. Excision biopsies of her Sister
Mary Joseph’s nodule and a subcutaneous epigastric
nodule revealed them to be subcutaneous metastases
from the colorectal adenocarcinoma (Figure 4). She did
not show significant improvement after two cycles of
treatment, except for the relief of the mass effect due to
the ‘giant’ ovarian tumors. It was decided to revert to
treatment for metastatic colon cancer alone (capecitabine).
She showed marked improvement and did not have to
undergo peritoneocentesis for ascites.
In December 2012 we conducted an array of immuno-
histochemistry (IHC) tests on the excised ovaries and
cutaneous lesions (Table 1). Doubts still existed over the
origin of the ovarian carcinoma. The cancer antigen
(CA)-125 stained negative (Figures 5 and 6). This is typ-
ical of primary ovarian mucinous carcinomas and colorec-
tal adenocarcinomas. It stains positive in primary
ovarian serous carcinomas. CDX2, a sensitive marker
and quite specific for colorectal carcinoma [11], was
positive (Figures 5 and 6). Carcinoembryonic antigen
(CEA) was also strongly and diffusely positive (Figures 5
and 6), as is usually the case in colorectal carcinomas. The
use of the CA-125 to CEA ratio may help to discriminate
gastrointestinal carcinoma from ovarian carcinoma [6].Figure 4 Hematoxylin and eosin-stained sections of skin. Photomicrog
being invaded by malignant glands. Photomicrograph B shows the malignFurther IHC with cytokeratin 7 and 20 was negative and
positive, respectively (Figure 6), making metastatic colo-
rectal carcinoma the definitive diagnosis [12].
In addition, we analyzed for microsatellite instability
(MSI) using the recommended microsatellite markers.
Analysis of MMR genes MLH1 and PMS1 was negative,
MSH2 weakly positive, and MSH6 was strongly positive.
This means she could be a case of Lynch syndrome or a
sporadic MSI-high (MSI-H) [2]. MSI-H means that two
or more markers are positive and at least 30% of the
markers show instability. Moreover, the modified Be-
thesda criteria also consider MSI-H positivity as marking
the presence of a MMR gene mutation.
Discussion
Our patient presents a scenario of multiple tumors, one
of which may not be diagnosed with certainty through
basic histopathological examination. Colorectal adeno-
carcinoma was first diagnosed 3 years ago. Following
surgery last year, a diagnosis of ovarian carcinoma with
cutaneous metastases of the colon carcinoma was made.
The initial diagnosis of a primary serous carcinoma of the
ovary was only changed to that of colorectal carcinoma
with metastases to the ovaries 1 month ago in response to
results from IHC tests.raph A (under ×4 magnification objective) shows the reticular dermis
ant glands under higher magnification.




Cancer antigen 125 Negative Negative
CDX2 Positive Positive
Carcinoembryonic antigen Positive Positive
Cytokeratin 7 Negative Not available
Cytokeratin 20 Positive Not available
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mary tumor, with or without metastases. In our patient
there are transperitoneal metastases with multiple
peritoneal seedlings and cutaneous nodules. Cutaneous
metastasis from a visceral malignancy is rare with an
incidence of 5.3% [6]. Our patient had a Sister Mary
Joseph’s nodule and other nodules around the previous
incision and periumbilical area. Previous literature de-
scribes this occurrence mostly around the incision scars
[8] and it is hypothesized that the mechanism is implant-
ation at the time of surgery [8,13]. Sister Mary Joseph’s
nodules are a result of transperitoneal-lymphatic spread.
Nodules are the most frequent clinical presentation of
cutaneous metastases [13,14].
Going by our working diagnosis of metastatic colorectal
cancer and primary ovarian cancer, she was classified as a
case of Lynch syndrome 2. Women with HNPCC-
associated colorectal cancer have a 12% lifetime risk for
ovarian cancer, meaning several of them will have more
than one cancer in their lifetime [15]. The only tumor com-
moner than ovarian cancer, is endometrial cancer. Confirm-
ation of HNPCC is done with molecular tumor tests and
blood genetic testing. Although we neither conducted com-
prehensive molecular tests for MMR proteins nor blood
genetic tests, we could still be dealing with a Lynch
syndrome given our other test results. However, it could
still be a sporadic case because up to 15% of them are also
associated with MSI. Further still we have no suggestive
family history. Of importance though, family disease history
and records are highly unreliable in the East African region.Figure 5 Immunohistochemically (diaminobenzidine) stained sections
malignant glands in the dermis staining positively with CDX2. Photomicrog
carcinoembryonic antigen. Photomicrograph C shows negative staining byIf indeed it is a case of Lynch syndrome (confirmed
through MMR protein and blood genetic tests), this
whole scenario may mean she has not yet developed a
second tumor (metachronous), or may already have one;
still covert. A screening strategy for common HNPCC-
associated cancers can then be instituted.
The conundrum of this case is the course of manage-
ment in relation to the unfolding clinical features follow-
ing the surgical treatment for the colorectal cancer
(extended right hemicolectomy) when put in context of
the histopathological diagnosis. Adjuvant chemotherapy
would be expected to deal well with the colorectal car-
cinoma. Development of new abdominal symptoms after
adjuvant treatment pointed to a possible recurrence.
Failure to improve after more chemotherapy could point
to a ‘resistant’ form of tumor, an inappropriate regimen
and/or a wrong initial diagnosis. A reassessment was
called for and done, resulting in another laparotomy with
a clinical diagnosis of ‘giant’ ovarian tumors (Figure 2).
Subsequent histopathological examination showed a
second independent tumor: primary ovarian carcinoma.
Up to 45% of secondary ovarian tumors are clinically
seen to be primary ovarian carcinomas and many are
misinterpreted as such on pathologic examination even
when there is a known intestinal carcinoma [16]. Failure
to improve on the cisplatin regimen led to reversion to
capecitabine. The benefits of this decision, coupled with
the salpingo-oophorectomy, are evident in the patient’s
clinical recovery. The surgery alone provided massive
cytoreduction of tumor. Bilateral oophorectomy for
ovarian metastasis from colorectal cancer has a good
impact in providing a disease-free period and improving
overall survival [4]. The current capecitabine regimen is
dealing quite well with the other peritoneal metastases.
However, we still treat this disease within the context of
a poor prognosis. Peritoneal dissemination is an adverse
prognostic factor [17].
While the patient continues treatment for metastatic
colorectal cancer, the possibility that we are dealing with
a Lynch 2 syndrome remains at the front of our minds.
There is a need to confirm the condition with bloodof skin (under ×4 magnification). Photomicrograph A shows
raph B shows the malignant glands positively stained by
cancer antigen 125.
Figure 6 Immunohistochemically (diaminobenzidine) stained sections of the ovary. Photomicrograph A shows the malignant glands
staining positively with cytokeratin (CK) 20 (×20 magnification). Photomicrograph B shows the malignant glands negatively stained by cancer
antigen 125 (×4 magnification). Photomicrograph C shows positive staining with CDX2 (×4 magnification). Photomicrograph D shows negative
staining with CK 7 (×4 magnification). Photomicrograph E shows positive staining with carcinoembryonic antigen (×10 magnification).
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other tumors. In the event that Lynch syndrome is
confirmed, our first step is counseling of the patient and
her relatives. Prophylactic hysterectomy is an option if
she is fit for surgery. Surveillance for other tumors
includes the following: colonoscopy of the remaining
colon annually; gastric and duodenal cancer screening –
upper gastrointestinal endoscopy annually; urothelial
cancer screening – annual urinalysis (cytology); and cen-
tral nervous system cancer screening – annual physical
examination [2].
Conclusions
Colorectal cancer in Uganda and the East African region
is getting increasingly recognized. More cases are being
diagnosed and treated by multidisciplinary teams of sur-
geons, medical oncologists, radiotherapists and patholo-
gists. Adequate documentation of patterns of colorectal
cancer and HNPCC-associated cancers is lacking. There
are no records of family trees of what are now described
as HNPCC families. Our case highlights several import-
ant issues encountered in the management of colorectal
cancer. This patient alone has shown the following:
firstly, a probable Lynch syndrome (at least the presence
of MMR gene mutation is evident) or a sporadic MSI-H
case; secondly, tumors can mimic others; and lastly,
cutaneous and bilateral ‘giant’ ovarian metastases from
colorectal cancer can arise contemporaneously. This is
an unexpected and unusual metastatic presentation.
The following learning points can be gathered from this
case: IHC and MSI analysis tests ought to be part of thediagnostic package in management of colorectal cancer;
multidisciplinary team collaboration is of paramount im-
portance; and, other specialists not often involved, may
frequently become core members of the team (gynecolo-
gists, urologists, dermatologists and neurosurgeons) both
in treatment and surveillance. In our setting, the role of
IHC in distinguishing ovarian metastases from primary
ovarian tumors, and the occurrence of MMR deficiencies
needs emphasis.
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